Hyperion hits IPO target with more shares at lower price
This article was originally published in Scrip
Executive Summary
Hyperion Therapeutics, the South San Francisco-based company developing Ravicti (glycerol phenylbutyrate) for rare urea cycle disorders and hepatic encephalopathy, has completed its initial public offering, raising $57.5 million in total. The company sold 5.75 million shares at $10 each, including a 0.75 million-share over-allotment option exercised in full by the underwriters.